{
  "id": 16880593,
  "title": "Chinese drug sector’s stature grows at major cancer conference",
  "url": "https://urgent.news/2026/10/28/chinese-drug-sectors-stature-grows-at-major-cancer-conference",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T10:00:13.000Z",
  "source": {
    "name": "SCMP Business",
    "slug": "scmp-business",
    "url": "https://www.scmp.com/business/china-business/article/3372422/chinese-drug-sectors-stature-grows-major-cancer-conference"
  },
  "original_language": "en",
  "account": null,
  "summary": "Chinese drug manufacturers showcased promising trial results for new cancer treatments at the European Society for Medical Oncology (Esmo) Congress, highlighting the growing international influence of China's biotech sector. Among the 96 late-breaking abstracts presented, Chinese research accounted for 29, with five of the 12 studies selected for the prestigious presidential symposium. Notable successes include Sichuan Kelun-Biotech Biopharmaceutical's ADC drug sacituzumab tirumotecan (sac-TMT), which showed a 32% reduction in the risk of death for patients with advanced or recurrent endometrial cancer. Additionally, Hansoh Pharmaceutical's bone cancer drug risvutatug rezetecan (Ris-Rez) demonstrated a 67% reduction in disease progression or death for patients with progressed or relapsed osteosarcoma. While not all Chinese firms fared well, the conference provided significant validation for several innovative cancer treatments.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}